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             Until recently, primed CD4 Th cells were con-
sidered to segregate into two distinct popula-
tions, each producing its own set of cytokines 
and mediating separate eff  ector functions (  1  ). 
Th1 cells produce IFN-    , and mediate activa-
tion of macrophages and induction of delayed-
type hypersensitivity responses. Th2 cells produce 
IL-4, IL-5, IL-10, and IL-13, which provide 
help for B cell function and are important in 
IgG switching, IgE production, and eosinophilic 
infl  ammation (  2  ). 
  T-bet is a Th1-specifi  c T-box transcription 
factor that plays a crucial role in Th1 develop-
ment, in part via the induction of IFN-    . T-bet 
not only induces Th1 development but also ac-
tively suppresses Th2 diff  erentiation, and more 
remarkably, introduction of T-bet into fully 
Th2-diff  erentiated CD4 T cells triggers conver-
sion to a Th1 phenotype. In the absence of T-bet, 
CD4 T cells fail to diff  erentiate into the Th1 
lineage and default to a Th2 fate. Mice with 
homozygous deletion of T-bet show normal 
lymphoid development but fail to generate 
functional Th1 responses, have impaired regula-
tion of antibody isotype class switching, and are 
protected from several T cell  –  mediated autoim-
mune diseases but show evidence of heightened 
allergic (Th2) responses (  3  ). 
  It has been proposed that a Th1 phenotype 
promotes allograft rejection via IFN-      –  induced 
activation of macrophage function and up-reg-
ulation of MHC class II antigen expression that 
favors T cell allosensitization. In contrast, the 
Th2 phenotype has been proposed to favor long-
term graft survival in some models (  4  ). Thus, in 
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  T-bet plays a crucial role in Th1 development. We investigated the role of T-bet in the 
development of allograft rejection in an established MHC class II  –  mismatched (bm12 into 
B6) model of chronic allograft vasculopathy (CAV). Intriguingly, and in contrast to IFN-
          /      mice that are protected from CAV, T-bet      /      recipients develop markedly accelerated 
allograft rejection accompanied by early severe vascular infl  ammation and vasculopathy, 
and infi  ltration by predominantly IL-17  –  producing CD4 T cells. Concurrently, T-bet      /      mice 
exhibit a T helper type 1 (Th1)  –  defi  cient environment characterized by profound IFN-     
defi  ciency, a Th2 switch characterized by increased production of interleukin (IL) 4, IL-5, 
IL-10, and IL-13 cytokines, as well as increased production of the proinfl  ammatory cyto-
kines IL-6, IL-12p40, and IL-17. Neutralization of IL-17 inhibits accelerated allograft 
rejection and vasculopathy in T-bet      /      mice. Interestingly, CD4 but not CD8 T cell defi  -
ciency in T-bet      /      mice affords dramatic protection from vasculopathy and facilitates long-
term graft acceptance. This is the fi  rst study establishing that in the absence of 
Th1-mediated alloimmune responses, CD4 Th17 cells mediate an aggressive proinfl  amma-
tory response culminating in severe accelerated allograft rejection and vasculopathy. These 
results have important implications for the development of novel therapies to target this 
intractable problem in clinical solid organ transplantation. 
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groups;   Fig. 1 A  ).   Further, grafts harvested from T-bet      /      
recipients 2 wk after transplantation were notable for histo-
logical signs of severe vascular infl  ammation and vasculopa-
thy, characterized by perivascular and intraluminal leukocytic 
infi  ltration, that were entirely absent in the case of IFN-          /      
recipients (  Fig. 1 B  ). Interestingly, grafts from the T-bet      /      
recipients were heavily infi  ltrated with PMNs (including 
eosinophils and neutrophils) compared with a predominantly 
mononuclear infi  ltration in the case of the WT recipients 
(  Fig. 1 C   and   Table I  ).   Because the PMN-dominant infi  l-
trate is also consistent with antibody-mediated rejection, 
we performed bm12 heart transplants in T-bet/Ig double 
KO (DKO) recipients that lacked both T-bet and mature B 
cells. Interestingly, T-bet/Ig DKO recipients also rejected 
the bm12 heart grafts with the same tempo as T-bet      /      re-
cipients (MST of 15 d in the T-bet      /      group vs. 14 d in the 
T-bet/Ig DKO group;   n   = 6 in each group; P = 0.8676;   Fig. 
1 A  ), and the pathology, including PMN infi  ltration, of the 
grafts harvested from T-bet/Ig DKO mice was very similar to 
those harvested from T-bet      /      recipients, indicating no role 
of antibodies or B cells in this model (not depicted). 8 wk af-
ter transplantation, grafts from the IFN-          /      recipients dem-
onstrated an intermediate pattern of infi  ltration, with more 
PMNs and fewer mononuclear cells compared with WT re-
cipients. As previously reported (  11  ), we also noted that IFN-
          /      mice demonstrated no evidence of allograft vasculopathy 
up to 8 wk after engraftment, in contrast to WT recipients in 
which occlusive CAV was noted in 50% of the vessels exam-
ined (  Fig. 1 B  ). 
  These observations were at fi  rst somewhat surprising in 
that T-bet      /      mice rejected the grafts despite exhibiting a Th1-
defi  cient environment, characterized by profound IFN-     
defi  ciency and increased Th2 cytokines, whereas many Th1-
dominated diseases are repressed in T-bet defi  ciency (  13  –  15  ). 
Further, STAT4      /      mice, which like T-bet      /      mice exhibit 
a Th1-defi  cient environment, are in contrast protected from 
CAV (  12  ). However, paradoxical results have been obtained 
involving the STAT1  –  T-bet  –  STAT4  –  IFN-     axis in various 
models of auto- and alloimmunity. For example, STAT1      /      
and IFN-          /      mice are susceptible to EAE, whereas T-bet      /      
and STAT4      /      mice are resistant (  15, 18  ). Some of these in-
consistencies are now beginning to be unraveled by the ap-
preciation of a novel, IL-17  –  secreting Th cell lineage termed 
Th17 as a mediator of tissue infl  ammation. In view of this 
and the peculiar pattern of graft-infi  ltrating leukocytes con-
sisting of predominantly PMNs, we examined the grafts 
showing severe vascular infl  ammation for the presence of 
IL-17  –  producing cells. 2 wk after transplantation, when the 
grafts from T-bet      /      recipients had undergone rejection, 
there was infi  ltration of PMNs along with CD4 and CD8 T 
cells with severe vascular infl  ammation and vasculopathy that 
were entirely absent in IFN-          /      recipients. Besides intense 
PMN infi  ltration observed by light microscopy (  Fig. 1 C  ), 
immuno  fl  uorescence staining of the grafts indicated that both 
CD4 and CD8 T cells were present, but the majority of the 
graft-infi  ltrating lymphocytes in T-bet      /      recipients were 
the transplant setting, it was widely believed that allograft re-
jection is predominantly a Th1-mediated immune response, 
although this conclusion was challenged by data in cytokine-
defi  cient mice that indicated that rejection could proceed in 
the absence of IL-2 or IFN-    . Mice defi  cient in the hallmark 
Th1 cytokine IFN-     rapidly reject fully mismatched cardiac 
allografts, as do mice lacking STAT4, a transcription factor as-
sociated with the development of Th1 responses (  5  –  7  ). Th2 
cytokines, on the other hand, have also been noted in grafts 
undergoing acute vascular rejection (  8, 9  ). As a result, the va-
lidity of the Th1/Th2 paradigm in transplantation has been 
questioned (  10  ). Nevertheless, in MHC class II  –  mismatched 
cardiac allograft models, transplanted hearts are protected from 
chronic allograft vasculopathy (CAV) in both STAT4- and 
IFN-      –  defi  cient mice, suggesting a key role for IFN-     and/or 
Th1 CD4 T cells in the development of subacute immune-
mediated vascular injury and CAV (  11, 12  ). 
  We hypothesized that in the absence of T-bet, a Th2-
predominant environment in combination with impaired CD8 
eff  ector function would result in inhibition of destructive al-
loimmune responses and could promote transplantation tol-
erance and prevent the development of CAV. This hypothesis 
is supported by studies in Th1-mediated autoimmune disease 
models in which T-bet defi  ciency confers protection (  13  –  15  ), 
as well as earlier studies in chronic rejection models in which 
STAT4- and IFN-      –  defi  cient mice are protected from CAV 
(  11, 12  ). However, in contrast to our a priori hypothesis, we 
now report for the fi  rst time the role of T-bet in alloimmunity, 
and show that T-bet defi  ciency contributes to the develop-
ment of aggressive CD4 Th17 cell  –  mediated infl  ammatory 
alloimmune responses that ultimately culminate in acceler-
ated rejection and vasculopathy in an established model of 
chronic rejection. 
    RESULTS   
  T-bet defi  ciency accelerates cardiac allograft rejection 
in a model of CAV 
  T-bet expression appears to be critical for the development of 
a variety of infl  ammatory autoimmune diseases classically 
considered related to Th1 immunity, such as experimental 
autoimmune encephalomyelitis (EAE), collagen-induced ar-
thritis, Crohn  ’  s disease, and type 1 diabetes (  13  –  15  ). Allograft 
rejection is also considered a predominantly Th1 immune re-
sponse. Moreover, IFN-     is a key regulatory cytokine associ-
ated with chronic allograft rejection and is thought to play a 
critical role in the pathogenesis of CAV (  11  ). Therefore, we 
investigated the role of T-bet in alloimmune responses and 
the development of CAV in an established MHC class II  –
  mismatched model (bm12 into C57BL/6) of CAV, where 
vascularized cardiac allografts survive long term without im-
munosuppression but develop CAV (  16, 17  ). Unexpectedly, 
T-bet      /      mice (  n   = 6) rejected their grafts with a median 
survival time (MST) of 15 d compared with WT (  n   = 8) and 
IFN-          /      (  n   = 6) mice in which 75% (two out of eight grafts 
were rejected at days 39 and 41) and 100% of grafts survived 
for   >  60 d, respectively (P   <   0.002 compared with both JEM VOL. 205, December 22, 2008 
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IL-17  –  producing CD4 T cells (  Fig. 2  ).   There were hardly 
any and no IL-17  –  producing cells in grafts from WT and IFN-
          /      recipients, respectively. Further, there were no NK cells 
and all of the T cells expressed the         TCR, indicating that 
there were no         T cells infi  ltrating the grafts from T-bet      /      
recipients (not depicted). Collectively these results suggest 
that T-bet negatively regulates the development of Th17 
cells that mediate the vascular infl  ammation and acute rejec-
tion in a model of CAV. 
    Figure 1.         T-bet defi  ciency accelerates cardiac allograft rejection 
characterized by severe vasculopathic changes and PMN infi  ltration.  
(A) MHC class II  –  mismatched cardiac allograft survival (bm12 into 
C57BL/6) in WT, T-bet     /   ,  IFN-      /    , and T-bet/Ig DKO recipients (  n   = 8 in 
WT, and   n   = 6 in T-bet     /   ,  IFN-      /    , and T-bet/Ig DKO groups). Survival 
data are presented as a Kaplan-Meier plot. (B) Pathology (top, H  & E  stain-
ing; bottom, elastin staining) of bm12 cardiac allografts from WT, T-
bet     /    , and IFN-       /     recipients at 2 and 8 wk after transplantation. Note 
the severe vascular infl  ammation in the T-bet     /     recipient and the normal 
vascular integrity in the IFN-       /     recipient in contrast to that of the WT 
recipient even at 8 wk after engraftment. Bars, 20   μ  m. (C) Pathology (H  & E 
staining) of bm12 cardiac allografts from WT, T-bet     /    , and IFN-       /    
recipients at 2 wk after transplantation (top, low magnifi  cation; bottom, 
high magnifi  cation) showing severe PMN infi  ltration (both neutrophils 
and eosinophils) in the T-bet     /     recipients and minimal PMN (predomi-
nantly eosinophilic) infi  ltration in IFN-       /     recipients, in contrast to mod-
est mononuclear infi  ltration in WT recipients. Insets show infi  ltrating cell 
morphology. Histology results presented are from one experiment and are 
representative of three independent experiments. Bars, 20   μ  m.     
 
  T-bet defi  ciency promotes CD4 and CD8 T cell effector 
memory differentiation and proliferation during 
an alloimmune response 
  To investigate whether T-bet defi  ciency, in addition to pro-
moting Th17 cells, had any eff  ect on CD4 and CD8 eff  ector 
memory T cell (T  EM  ) populations and proliferation in re-
sponse to alloantigens, we fi  rst evaluated the frequency of T 
cells bearing the T  EM   phenotype (CD44  hi  CD62L  low  ) in the 
peripheral blood of bm12 graft recipients 2 wk after transplan-
tation. We found that the activation of CD4 T cells in T-
bet      /      and IFN-          /      recipients (11.8   ±   0.2% and 13.3   ±   
3.4%, respectively) was slightly but signifi  cantly higher than in 
WT recipients (9   ±   0.2%; P   <   0.05). Further, the percentage 
of CD8 T cells with T  EM   phenotype in T-bet      /      recipients 
(32.3   ±   2.4%) was markedly higher than in IFN-          /      and 
WT recipients (9.56   ±   3.1% and 4.9   ±   1.5%, respectively; P   <   
0.001), with the majority of the CD8 T cells in T-bet      /      re-
cipients expressing low levels of CD62L (  Fig. 3 A  ).   These 
fi  ndings are consistent with recent reports of increased CD8-
central/memory T cell generation in T-bet      /      mice (  19  ). 
  Next, to investigate the impact of T-bet defi  ciency on T 
cell proliferation in vivo in response to alloantigen, we adop-
tively transferred T-bet      /      T cells into irradiated bm12 mice, 
and compared their proliferation and apoptosis with that of 
WT and IFN-          /      T cells. T-bet      /      CD4 T cells exhibited 
enhanced in vivo proliferation (24.6   ±   4.6% in T-bet      /      vs. 
11.6   ±   1.7% and 12.7   ±   2% in the case of WT and IFN-          /      
T cells; P   <   0.05 for both groups) and were somewhat more 
resistant to apoptosis (44.9   ±   2.2% in T-bet      /      vs. 59.7   ±   
4.2% and 64.4%   ±   2.3 in WT and IFN-          /      T cells; P   <   
0.005 for both groups). T-bet      /      CD8 T cell proliferation 
was also more pronounced (42.3   ±   4.4% vs. 19.8   ±   3% and 
14.8   ±   2.4% in T-bet      /      vs. WT and IFN-          /      T cells; P   <   
0.001 for both groups). However, more of the proliferating 
T-bet      /      CD8 T cells underwent apoptosis than WT and 
IFN-          /      CD8 T cells (57.3   ±   5.2% vs. 45.1   ±   1.4% and 
45.3   ±   2.2%, respectively; P   <   0.05 for both groups), ex-
plaining the lower absolute numbers of CD8 T cells in T-
bet      /      recipients (unpublished data). 
  A reciprocal relationship between the development of 
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cytes in T-bet      /      recipients were IL-17  –  producing CD4 T 
cells (  Fig. 2  ). We therefore examined alloantigen-specifi  c 
production of Th1 (IFN-    ), Th2 (IL-4, IL-5, IL-10, and IL-
13), and the proinfl  ammatory cytokines IL-2, TNF-    , IL-6, 
IL-17, IL-12p40, and IL-12p70 in WT, IFN-          /     , and T-
bet      /      recipients of bm12 cardiac allografts. Consistent with 
previous observations, T-bet      /      and IFN-          /      splenocytes 
produced signifi  cantly less Th1 cytokine IFN-     and more 
Th2 cytokines IL-4, IL-5, IL-10, and IL-13 (  Fig. 4  ).   Interest-
ingly, splenocytes from T-bet      /      recipients compared with 
those from WT or IFN-          /      recipients produced signifi  cantly 
higher amounts of proinfl  ammatory cytokines IL-6 (339   ±   
10.5 vs. 75.3   ±   25.9 and 208   ±   44.5 pg/ml, respectively; P   <   
0.01), IL-17 (337   ±   94.4 vs. 138.4   ±   68.3 and 95.8   ±   29.8 
pg/ml, respectively; P   <   0.05), and IL-12p40 (18,383.33   ±   
1,522.38 vs. 11,335   ±   1,391.89 and 12,200   ±   433.59 pg/ml, 
respectively; P   <   0.002). Notably, IL-12p70 (representing IL-12, 
a heterodimer of IL-12p35 and IL-12p40) levels were not sig-
nifi  cantly diff  erent between the three groups (unpublished data), 
orchestrated by IL-6 and TGF-     has been recently demon-
strated (  20  ). To investigate whether a decrease in Foxp3  +   T 
reg cells is responsible for the increase in CD4 and CD8 T 
cells bearing the T  EM   phenotype, we examined the CD4  + 
CD25  +  Foxp3  +   T reg cell population in the peripheral blood 
2 wk after transplantation. No signifi  cant diff  erence was found 
among WT, IFN-          /     , and T-bet      /      recipients (6.8   ±   1.4%, 
6.25   ±   2.6%, and 7.7   ±   1.8%, respectively; P   >   0.05 among 
all groups;   Fig. 3 B  ). These observations are consistent with 
a previous report that there was no defect in the numbers of 
T reg cells in the absence of IFN-     or T-bet (  21  ). Collec-
tively, an alloimmune response in the setting of T-bet defi  -
ciency is characterized by an increased proliferation of T cells 
and an expansion of CD4 and CD8 T  EM   cells. This, coupled 
with unaltered T reg cell numbers, results in a net increase in 
T cells of the T  EM   phenotype that may contribute to the ac-
celerated rejection and pathological changes in the graft in 
this model of CAV. 
  Up-regulation of Th2 and Th17 cytokine production 
by T-bet      /      recipients 
  T-bet controls Th cell polarization toward a Th1 phenotype 
(  3  ). In EAE studies, clinical improvement correlated with re-
duced T-bet expression, reduced IFN-     production, and a 
reciprocal increase in the Th2 transcription factor GATA3 in 
splenocytes (  15  ). Recently, it has been noted that both IFN-     
and T-bet repress the diff  erentiation of Th17 cells (  18, 22  ). 
Further, T-bet expression has been reported to be a critical 
determinant of Th1 versus Th17 cell fate (  23  ). Moreover, T-
bet appears to negatively regulate certain autoimmune diseases 
by suppressing IL-17 production (  21, 24  ). As shown below, 
we noted that the majority of the graft-infi  ltrating lympho-
    Table I.        Phenotype of graft-infi  ltrating leukocytes in WT, 
IFN-       /    , and T-bet     /     recipients 
Infi  ltrating cells WT  
  (day 60)
IFN-          /       
  (day 60)
T-bet      /       
  (day 14)
Lymphocytes 57.2   ±   13.1 2.7   ±   1.3 17.9   ±   4.2
Macrophages 24.8   ±   6.1 6.8   ±   1.6 22.3   ±   7.2
Neutrophils 3.9   ±   3.3 0.5   ±   0.7 16.7   ±   4.2
Eosinophils 0 13.3   ±   4.4 88.1   ±   11
Total 85.9   ±   15.5 23.3   ±   4.9 145   ±   17.6
Five high-power fi  elds were counted per slide, with one slide each from fi  ve to six 
heart grafts per group. Results are presented as mean numbers of cells   ±   SD.
    Figure 2.         IL-17  –  expressing graft-infi  ltrating lymphocytes in T-bet      /      recipients.   Immunofl  uorescence staining and confocal microscopy of heart 
allografts harvested 2 wk after transplantation for IL-17 expression by CD4 and CD8 T cells. IL-17 expression by most of the CD4 (top) and some of the 
CD8 (bottom) graft-infi  ltrating T cells in the T-bet     /     recipients is seen in contrast to WT recipients (not depicted), where only a few of the infi  ltrating T 
cells express IL-17 and no IL-17  –  expressing cells were seen in grafts from IFN-       /     recipients (not depicted). Results presented are from one experiment 
and are representative of three independent experiments. Bars, 20   μ  m.     JEM VOL. 205, December 22, 2008 
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the CD4 cell population and are consistent with the observa-
tion that CD4 but not CD8 T cell defi  ciency or depletion in 
T-bet      /      recipients aff  ords dramatic protection from vascu-
lopathy and facilitates long-term acceptance of heart grafts 
(  Fig. 5 C  ). Collectively, these data indicate that T-bet in CD4 
cells plays a critical role in determining the fate and type of 
the alloimmune response. 
  Anti  –  IL-17 antibody inhibits accelerated cardiac allograft 
rejection in a model of CAV in T-bet      /      recipients 
  From the foregoing, it is reasonable to consider that IL-17  –
  producing Th17 cells play a critical role in mediating alloim-
mune responses. Further, blocking IL-17 with anti  –  IL-17 
antibody resulted in markedly reduced skin infl  ammation in a 
model of systemic autoimmunity (  21  ). We therefore adminis-
tered anti  –  IL-17 mAb or control Ig to T-bet      /      recipients of 
bm12 heart grafts and observed for graft survival to directly 
determine whether IL-17 neutralization can inhibit acceler-
ated cardiac allograft rejection in this model of CAV. Neutral-
ization of IL-17 with anti  –  IL-17 mAb indeed resulted in 
signifi  cant prolongation of allograft survival in T-bet      /      re-
cipients compared with the group that received control IgG 
(MST of 38 vs. 15 d, respectively; P   <   0.01;   Fig. 6 A  ).   The 
protection from acute rejection, although signifi  cant, was not 
complete and may have been caused by the relatively brief 
duration of anti  –  IL-17 mAb administration. We then, as 
above, examined alloantigen-specifi  c production of Th1, Th2, 
indicating that the diff  erences in levels of IL-12p40 could be 
caused by diff  erences in IL-23 (a heterodimer of IL-12p40 
and IL-23p19) production (  25  ), consistent with previous re-
ports of increased IL-17 and IL-23 production in autoimmune 
disease models in T-bet      /      mice (  21, 24  ). However, on direct 
measurement of IL-23 by ELISA we noted that IL-23 pro-
duction by splenocytes harvested from bm12 heart allograft 
recipients was generally low and not diff  erent between T-
bet      /      and IFN-          /      recipients (2.67   ±   2.31, 5.47   ±   7.49, 
and 5.7   ±   7.35 pg/ml in WT, IFN-          /     , and T-bet      /      re-
cipients, respectively; P = NS between all groups). Collec-
tively, in the presence of increased IL-6 and in the absence of 
Th1-polarizing conditions and the loss of direct negative reg-
ulatory eff  ect of T-bet on Th17 cells in the T-bet      /      recipi-
ents, a positive feedback loop for the generation of Th17 cells 
is established, ultimately resulting in a heavily skewed im-
mune response toward the Th17 phenotype. 
  Proinfl  ammatory cytokine production and accelerated 
cardiac allograft rejection in a model of CAV 
in T-bet      /      mice is dependent on CD4 T cells 
  Both CD4 and CD8 lymphocytes contribute to CAV devel-
opment via secretion of IFN-    , a known mediator of CAV in 
this model (  26  ). Recently, it has been suggested that T-bet  –
  expressing CD8 T cells mediate suppression of experimental 
autoimmune myocarditis (  24  ). To evaluate the relative impor-
tance of T-bet defi  ciency in CD4 or CD8 T cell compart-
ments in mediating the accelerated rejection, we injected CD4 
or CD8 depleting mAb into T-bet      /      recipients of bm12 
hearts. CD8 depletion resulted in a slight prolongation of MST 
from 15 to 21 d (P   <   0.001;   Fig. 5 A  ).   In contrast, CD4 deple-
tion resulted in a dramatic prolongation of allograft survival 
(  >  60 d) in T-bet      /      recipients (  Fig. 5 A  ). In addition, we 
transplanted bm12 hearts into CD4/T-bet DKO and CD8/T-
bet DKO recipients. CD4/T-bet DKO recipients, similar to 
the CD4-depleted T-bet      /      recipients above, also accepted 
the grafts for   >  60 d, whereas CD8/T-bet DKO mice rejected 
the heart grafts with an MST of 19 d (  Fig. 5 A  ). Further, path-
ological examination of the grafts from CD4-depleted T-
bet      /      and CD4/T-bet DKO recipients revealed only mild 
vasculopathy in 20 and 12.5% of the vessels, respectively, 8 wk 
after transplantation, whereas grafts from CD8-depleted T-
bet      /      or CD8/T-bet DKO recipients showed severe vascu-
lopathy 3 wk after transplantation (  Fig. 5 B  ). These data are in 
keeping with the observation that the majority of the IL-17  –
  producing graft-infi  ltrating lymphocytes in T-bet      /      recipi-
ents were CD4 T cells ( Fig. 2 ) and indicate that T-bet expressed 
in the CD4 rather than CD8 T cell compartment prevents ac-
celerated rejection in this model of CAV. 
  Further, splenocytes from T-bet/CD4 DKO recipients 
compared with those from T-bet      /      and T-bet/CD8 DKO 
recipients produced signifi  cantly less IL-6 (12.9   ±   3.8 vs. 
940.7   ±   176.3 and 1,240.5   ±   215.6 pg/ml, respectively; P   <   
0.01) and IL-17 (7.8   ±   4.6 vs. 210.2   ±   73.4 and 113.1   ±   61.2 
pg/ml, respectively; P   <   0.01) cytokines. These data indicate 
that both of these cytokines are predominantly produced by 
    Figure 3.         T-bet defi  ciency promotes CD4 and CD8 T cell effector/
memory differentiation and proliferation in MHC class II  –  mis-
matched cardiac allograft recipients.   (A) FACS analysis of lymphocytes 
in the peripheral blood of WT, IFN-       /   ,  and  T-bet    /     recipients bearing a 
CD44  hi CD62L low   effector/memory phenotype gated on either CD4 (top) or 
CD8 (bottom) T cell populations. Percentages of cells are shown. 
(B) CD25  + /Foxp3 +   regulatory CD4 T cells in the MHC class II  –  mismatched 
cardiac allograft recipients. Gates were set on the CD4  +   population,  and 
percentages of cells are shown. Bar graphs show means   ±   SD. All results 
are representative of at least three different sets of experiments.     3138 T-BET REGULATES CD4 TH17 CELLS AND ALLOGRAFT VASCULOPATHY   | Yuan et al. 
IL-17 cytokine production in T-bet      /      recipients and infi  l-
tration of vascular lesions with IL-17  –  producing CD4 T cells, 
we conclude that CD4 Th17 cells are the main cells responsi-
ble for mediating the accelerated rejection and CAV in T-
bet      /      recipients. 
    DISCUSSION   
  Since the original description of Th lymphocyte subsets (Th1 
and Th2) and their divergent eff  ector functions, each has been 
linked with the development of specifi  c diseases or immune 
responses, including transplant rejection or tolerance (  28, 29  ). 
It has been postulated that Th1 cells are critically involved in 
the development of allograft rejection, whereas Th2 cells are 
involved in promoting transplantation tolerance (  29  ). T-bet is 
believed to be crucial for the development of a variety of in-
fl  ammatory diseases by virtue of being the master regulator of 
Th1 diff  erentiation (  30  ). T-bet      /      mice are resistant to EAE 
(  13  ), and silencing T-bet by small interfering RNA specifi  c 
for T-bet at the time of EAE induction reduced the incidence 
and severity of disease, indicating that T-bet is critical for the 
diff  erentiation of autoreactive T cells. Further, silencing T-bet 
after disease onset signifi  cantly improves the clinical course 
of established EAE (  15  ). Intriguingly, we found that T-bet 
defi  ciency in cardiac allograft recipients, on the contrary, 
accelerates rejection in a model of CAV despite exhibiting a 
Th1-defi  cient environment characterized by a profound defi  -
ciency of IFN-     and increased Th2 cytokines. This was par-
ticularly surprising because IFN-     is thought to play a critical 
role in the pathogenesis of CAV, and either STAT4 or IFN-     
defi   ciency confers protection from CAV in this model 
(  11, 12  ), raising questions about the notion that IFN-     is the 
key regulatory cytokine associated with chronic allograft re-
jection. However, intriguing and paradoxical results have been 
obtained involving the STAT1  –  T-bet  –  STAT4  –  IFN-     axis 
in various models of auto- and alloimmunity. For example, 
STAT1      /      mice and IFN-          /      mice are susceptible to EAE, 
whereas T-bet      /      and STAT4      /      mice are resistant (  15, 18  ). 
IFN-     has been implicated in the acute rejection process in 
and proinfl  ammatory Th17 cytokines in the anti  –  IL-17 mAb 
or control Ig  –  treated T-bet      /      recipients of bm12 cardiac al-
lografts 14 or 40 d after transplantation. Consistent with our ear-
lier observations, splenocytes from T-bet      /      recipients at each 
time point produced very little Th1 cytokine IFN-     (  Fig. 6 B  ). 
Further, at days 14 and 40, splenocytes from T-bet      /      recipients 
treated with anti  –  IL-17 mAb in comparison to those from 
control Ig  –  treated T-bet      /      recipients at day 14 produced 
signifi  cantly less of the proinfl  ammatory cytokines IL-17 (13.6   ±   
0.43 and 72.3   ±   81.12 vs. 337   ±   111.85 pg/ml, respectively; 
P   <   0.01) and IL-12p40 (3.42   ±   and 1.12   ±   0.43 vs. 18,433   ±   
152.75 pg/ml, respectively; P   <   0.001). Notably again, IL-
12p70 (representing IL-12, a heterodimer of IL-12p35 and 
IL-12p40) levels were not signifi  cantly diff  erent between the 
three groups (unpublished data). Interestingly, splenocytes 
from T-bet      /      recipients treated with anti  –  IL-17 mAb in 
comparison to those from control Ig  –  treated T-bet      /      recipi-
ents produced signifi  cantly higher amounts of the Th2 cyto-
kines IL-4 (174.83   ±   22.12 and 200.8   ±   vs. 22.2   ±   33.5 pg/ml, 
respectively; P   <   0.01) and IL-5 (2,448.33   ±   675.79 and 641   ±   
36.11 vs. 204.7   ±   19 pg/ml, respectively; P   <   0.001). IL-10 
levels were not signifi  cantly diff  erent between the three groups; 
however, IL-13 production was initially increased at day 14 
and then diminished at day 40 in anti  –  IL-17  –  treated groups 
(  Fig. 6 B  ). IL-6 is upstream of IL-17 in the Th17 diff  erentia-
tion pathway (  27  ); consequently, IL-6 production is markedly 
elevated in anti  –  IL-17  –  treated groups (1,405.2   ±   203.44 and 
726   ±   116.9 vs. 262   ±   12.12 pg/ml, respectively; P   <   0.001). 
Pathological examination of heart allografts from T-bet      /      
recipients treated with anti  –  IL-17 mAb at day 14 revealed mini-
mal vascular infl  ammation and no changes of CAV (  Fig. 6 C   
and   Table II  ).   However, examination at day 40, when the 
anti  –  IL-17  –  treated T-bet      /      recipients had rejected the heart 
allografts, revealed considerable leukocytic infi  ltration in the 
parenchyma but minimal CAV (  Fig. 6 C   and   Table II  ). These 
data are consistent with previous reports of reduced skin 
infl  ammation with IL-17 neutralization in a model of sys-
temic autoimmunity (  21  ). Collectively, with the increased 
    Figure 4.         Up-regulation of Th2 and Th17 proinfl  ammatory cytokine production by T-bet      /      allograft recipients of bm12 hearts.   Th1,  Th2, 
and Th17 proinfl  ammatory cytokine production by the splenocytes of WT, IFN-       /    , and T-bet     /     recipients of bm12 heart grafts assessed by the Lu-
minex assay. IL-12 data are presented separately because of the need to use a different scale. Results presented are means   ±   SD and are representative 
of at least three independent experiments.     JEM VOL. 205, December 22, 2008 
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allograft dysfunction independent of IL-12p70 or IL-23 (  38  ). 
Collectively, in the presence of increased IL-6 and in the 
absence of Th1-polarizing conditions and the loss of a di-
rect negative regulatory eff  ect of T-bet on Th17 cells in the 
T-bet      /      recipients, a positive feedback loop for the generation 
of Th17 cells is established, ultimately resulting in a heavily 
skewed immune response toward the Th17 phenotype. In-
terestingly, IL-17 neutralization in T-bet      /      recipients inhib-
ited accelerated cardiac allograft rejection and was associated 
with markedly reduced IL-17 and IL-12p40 production (  Fig. 6, 
A and B  ). However, production of IL-6 and Th2 cytokines, 
including IL-13, was actually increased with IL-17 neutral-
ization, indicating that IL-17 is downstream of IL-6 and that 
IL-17 is critical for mediating cardiac allograft rejection and vas-
culopathy. In an antigen-induced allergic airway infl  ammation 
recipients of allografts, whereas IFN-     defi  ciency  has  also 
been reported to result in severe vascular infl  ammation lead-
ing to acute rejection and to interfere with tolerance induc-
tion ( 31  ). The diff  erences seen in Th17 response after targeting 
T-bet with small interfering RNA in the EAE model (  15  ) 
versus the CAV model in our studies are likely related to the 
diff  erences in the model, mode of priming, precursor T cell 
frequency, strength of TCR stimulation, and partial versus 
complete T-bet defi  ciency. Interestingly, recent studies have 
shown that T-bet acts as a negative regulator of Th17-medi-
ated immune responses in two diff  erent models of autoim-
munity (  21, 24  ). In a model of experimental autoimmune 
myocarditis, heightened disease severity in T-bet      /      mice was 
suggested to be caused by increased CD4 T cell  –  mediated IL-
17 production in the heart (  24  ). Lohr et al., in another model 
of systemic autoimmune disease, reported worsening of dis-
ease in T-bet      /      mice, suggesting a reciprocal relationship 
between Th1 responses and IL-17 production indicating that 
IL-17 is an important cytokine in tissue infl  ammation (  21  ). 
Our observation of accelerated rejection in T-bet      /      recipi-
ents associated with severe vascular infl  ammation character-
ized by PMNs and IL-17  –  producing T cell infi  ltration are in 
keeping with these previous reports of T-bet as a negative 
regulator of Th17-mediated immune responses in vivo. These 
results suggest that T-bet negatively regulates the develop-
ment of Th17 cells that mediate the vascular infl  ammation 
and acute rejection in a model of CAV. 
  Interestingly, the accelerated allograft rejection and vas-
culopathy are associated with increased production of the 
proinfl  ammatory cytokines IL-6, IL-17, and IL-12p40. These 
observations are consistent with previous reports of increased 
IL-17 production in autoimmune disease models in T-bet      /      
mice (  21, 24  ). T-bet decreases antigen receptor  –  induced IL-
17 production (  23  ). IL-23, on the other hand, promotes IL-
17 expression and the proliferation of IL-17  –  producing cells 
from a pool of memory T cells, thus playing an important 
role in maintaining Th17 eff  ector function (  32, 33  ). It has 
been proposed that in an infl   ammatory milieu, IL-6 and 
TGF-     together induce Th17 cells and up-regulate IL-23R, 
thereby allowing IL-23 to strengthen and sustain the Th17 
phenotype (  34  ). However, in this model of CAV, although 
IL-12p40 levels were elevated, IL-23 production in vitro by 
splenocytes from allograft recipients was minimal, indicating 
that IL-23  –  independent mechanisms may be responsible for 
the maintenance of the Th17 response. IL-12p40 is believed 
to have opposing immunomodulatory eff  ects in diff  erent ex-
perimental conditions; for example, IL-12p40 specifi  cally in-
hibited the eff  ects of IL-12 and IL-23 heterodimers (  35, 36  ), 
whereas IL-12p40 homodimers exacerbated cardiac allograft 
rejection by enhancing alloantigen-specifi   c Th2 develop-
ment (  37  ). However the latter study predated the discovery 
of Th17 cells, and the aggressive alloimmune responses were 
attributed to skewing of the immune response toward a Th2 
phenotype and Th17 responses were not examined. Further, 
in lung transplantation, enhanced epithelial production of IL-
12p40 homodimers was associated with progressive chronic 
    Figure 5.         T-bet      /      CD4 T cells produce proinfl  ammatory cytokines 
and mediate accelerated cardiac allograft rejection in the MHC class 
II  –  mismatched cardiac allograft model of CAV.   (A) Survival of alloge-
neic bm12 cardiac graft in CD4- or CD8-depleted (left) and CD4/T-bet or 
CD8/T-bet DKO (right) recipients (  n   = 4 in each group). Survival data are 
presented as Kaplan-Meier plots. (B) Pathology (elastin staining) of bm12 
cardiac allografts from CD4- or CD8-depleted T-bet     /     recipients at 8 and 3 wk, 
respectively, after transplantation. Note the signifi  cant vasculopathy in the 
CD8-depleted T-bet     /     recipient and, in contrast, the relatively normal vas-
cular integrity in the CD4-depleted T-bet     /     recipient even at 8 wk after 
engraftment. Bars, 20   μ  m. (C) IL-6 and IL-17 proinfl  ammatory cytokine 
production by splenocytes of T-bet     /    , CD4/T-bet DKO, and CD8/T-bet DKO 
recipients of bm12 heart grafts assessed by the Luminex assay. Bar graphs 
show means   ±   SD. Results presented are from one experiment and are rep-
resentative of three independent experiments.    3140 T-BET REGULATES CD4 TH17 CELLS AND ALLOGRAFT VASCULOPATHY   | Yuan et al. 
immune response, appears to be an attractive strategy for the 
inhibition of Th17 diff  erentiation. 
  IL-17 is a potent proinfl  ammatory cytokine that induces 
chemokine expression and leukocyte infi  ltration and medi-
ates tissue infl  ammation (  18  ). IL-17 induces granulopoiesis via 
G-CSF production and regulates neutrophil recruitment via 
CXC chemokine induction by epithelial cells (  43  ). Homo-
zygous deletion of IL-17RA abrogates the increase in splenic 
neutrophil progenitors induced by overexpression of IL-17A 
(  43  ). Further, in a model of acute trinitrobenzenesulfonic 
acid  –  induced colitis, mice defi  cient in IL-17RA expression 
were signifi   cantly protected from trinitrobenzenesulfonic 
acid  –  induced weight loss and colonic infl  ammation and sub-
stantially reduced PMN immigration into the colon (  44, 45  ). 
Neutralization of IL-17A homodimers strongly inhibits neu-
trophilic airway infl  ammation mediated by adoptive transfer 
of ovalbumin-specifi  c polarized Th17 cells and airway chal-
lenge with antigen (  46  ). In keeping with these, we noted 
intense PMN infi  ltration within the lesions of vascular in-
fl  ammation in grafts from T-bet      /      recipients; interestingly, 
however, the PMN infi  ltration consisted of both neutrophils 
and eosinophils, perhaps as a result of markedly increased Th2 
cytokines along with a Th17 immune response. Eosinophilic 
infi  ltration is well described in cardiac allografts associated 
with a Th2 immune response (  47  ). Further, neutralization of 
IL-17 in T-bet      /      recipients markedly reduced the vascular 
infl  ammation, particularly neutrophil infi  ltration, suggesting 
a link between IL-17 and neutrophil recruitment to the graft 
(  Fig. 6 C   and   Table II  ). 
  Despite the predominantly PMN infi  ltration, CD4 cells 
appear to be critical for the development of CAV, because 
CD4 depletion or defi  ciency in T-bet      /      recipients aff  ords 
complete protection from CAV and long-term allograft sur-
vival (  Fig. 5, A and B  ). Further, IL-6 and IL-17 production is 
markedly diminished in CD4/T-bet DKO recipients (  Fig. 5 C  ), 
indicating the CD4 cells are critical for the initiation of the 
aggressive Th17 alloimmune response. Moreover, there is an 
increase in proliferation of T cells and an expansion of CD4 
and CD8 T  EM   cells in T-bet      /      recipients (  Fig. 3 A  ). These 
fi  ndings are consistent with recent reports of increased CD8-
central/memory T cell generation in T-bet      /      mice (  19  ). 
Further, we examined whether this net increase in T cells of 
the T  EM   phenotype is caused by a defi  ciency in Foxp3  +   T reg 
cells, particularly because a reciprocal relationship between 
the development of pathogenic Th17 cells and Foxp3  +   T reg 
cells orchestrated by IL-6 and TGF-     has been recently dem-
onstrated (  20  ). In addition, IL-6, together with IL-1 and 
STAT3, induces genetic reprogramming of Foxp3  +   T reg 
cells (  48  ). However, we did not fi  nd a decrease in Foxp3  +   T 
reg cells in T-bet      /      recipients (  Fig. 3 B  ). These observations 
are consistent with a previous report that there was no defect 
in numbers of T reg cells in the absence of IFN-     or T-bet 
(  21  ). Whether the function of CD4  +  CD25  +  Foxp3  +   T reg 
cells in T-bet      /      mice is also unaltered remains to be investi-
gated. Further, the infl  ammatory milieu within the grafts in 
T-bet      /      recipients may promote the conversion of T reg 
model, T-bet inhibited diff  erentiation of both Th17 and IL-
13  –  producing Th2 cells (  39  ). In addition, IL-13 appears to 
down-regulate Th17 diff  erentiation in models of pulmonary 
and CNS infl  ammation (  40, 41  ). Therefore, targeting IL-13 
may not be benefi  cial in the prevention of Th17 immunity. 
On the other hand, IL-6 blockade inhibited the development 
of EAE, indicating that IL-6 targeting prevents diff  erentia-
tion of Th17 cells but does not inhibit committed Th17 cells 
(  42  ). Therefore, IL-6 blockade, particularly early in the allo-
    Figure 6.         IL-17 neutralization inhibits accelerated cardiac allograft 
rejection in a model of CAV in T-bet      /      mice.   (A) MHC class II  –  mis-
matched cardiac allograft survival (bm12 into C57BL/6) in T-bet     /     recipi-
ents treated with anti  –  IL-17 mAb (  n   = 4) or control IgG (  n   = 4). Survival 
data are presented as a Kaplan-Meier plot. (B) Th1, Th2, and Th17 proin-
fl  ammatory cytokine production, assessed by the Luminex assay at days 14 
or 40 after transplantation, by the splenocytes of T-bet     /     recipients  of 
bm12 heart grafts treated with control Ig or anti  –  IL-17 mAb. IL-12 data are 
presented separately because of the need to use a different scale. Results 
presented are means   ±   SD and are representative of three independent 
experiments. (C) Pathology of bm12 cardiac allografts from anti  –  IL-17 
mAb – treated  T-bet    /     recipients at 14 d after transplantation (left and 
middle, H  &  E staining; inset, infi  ltrating cell morphology), showing a de-
crease in PMN infi  ltration (particularly neutrophils), and at 40 d after trans-
plantation (right, elastin staining), showing minimal CAV. Bars, 20   μ  m.    JEM VOL. 205, December 22, 2008 
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seemingly inconsistent fi  ndings in models of Th1-mediated 
autoimmune infl  ammation such as EAE and collagen-induced 
arthritis in IFN-          /      or STAT1      /      mice (  13  ). Th17 immu-
nity has been implicated in various models of immune-mediated 
tissue injury, particularly in the absence of a Th1 environ-
ment (  21, 53, 54  ). Our studies have extended this novel para-
digm to the transplant setting, enabling us to explain transplant 
rejection by infl  ammatory processes mediated by Th17 cells 
in the absence of Th1-dominant immune responses. Indeed, 
IL-17 has been implicated in both experimental and human 
renal and lung allograft rejection (  51, 55  –  57  ). Further, IL-17 
promotes secretion of infl   ammatory cytokines by stromal 
cells and macrophages and promotes DC maturation. IL-17R:
Fc administration promoted cardiac allograft survival by in-
hibiting maturation of DC progenitors (  58  ), and local expres-
sion of soluble IL-17R by gene therapy prolonged cardiac 
allograft survival (  59  ). From the data presented in this paper, 
it is clear that CD4 Th17 cells are the major mediators of vas-
cular infl  ammation, thereby setting the stage for the progression 
of these lesions to CAV. We have shown that T-bet nega-
tively regulates this vascular infl  ammation and suppresses the 
development of CAV. Further, neutralization of IL-17 pre-
vents vascular infl  ammation and suppresses CAV. In conclusion, 
IL-17  –  producing CD4 Th17 cells are important in allograft 
rejection and may serve as a novel target of strategies for the 
prevention of transplant rejection and graft vasculopathy. 
  MATERIALS AND METHODS 
  Animals.     WT C57BL/6, B6.C-H2  bm12   (bm12), IFN-          /     , CD4      /     , Ig      /      
(B-less), and T-bet      /      mice, all on a C57BL/6 background, were purchased 
from the Jackson Laboratory. Mice defi  cient in both T-bet and CD4, CD8, or 
B cells were generated by crossbreeding. Genotyping was used to confi  rm ho-
mozygous deletion of the T-bet and CD4, CD8, or Ig genes. Experiments were 
approved by the Institutional Animal Care and Use Committee at the Harvard 
Medical School Center for Animal Resources and Comparative Medicine. 
  Heart transplantation and antibody treatment.     In the MHC class II 
mismatch model, bm12 mice were used as donors, and C57BL/6 WT, IFN-
          /     , T-bet      /     , T-bet      /     /CD4      /     , T-bet      /     /CD8      /     , or T-bet      /     /Ig      /     , 
all on C57BL/6 background, were used as recipients. Vascularized heart 
grafts were transplanted using a microsurgical technique as previously de-
scribed (  16  ). Depleting anti-CD4 (GK1.5) and -CD8 (2.43; both from Bio-
Express) were administered i.p. at a dose of 0.1 mg on days     6,     3, and     1. 
Neutralizing IL-17 mAb (MAB421; R  &  D Systems) was administered i.p. at 
a dose of 100   μ  g daily on days 0  –  3, followed by every other day until day 13 
after transplantation. Graft function was assessed by daily palpation of the ab-
domen. Rejection was defi  ned as complete cessation of cardiac contractility 
as determined by direct visualization. 
cells to Th17 phenotype in an IL-6  –  dependent manner, as 
has been recently demonstrated in the context of priming 
with activated DCs (  49  ). Whether this is the case in our 
model needs further investigation. CD4 Th17 cells have been 
implicated in many autoimmune diseases (  50  ), and collagen 
type V  –  specifi  c Th17 cells contribute to obliterative bron-
chiolitis in human lung transplants (  51  ). Therefore, it is con-
ceivable that the cardiac allograft rejection in T-bet      /      
recipients is mediated by Th17 cells reacting against self-anti-
gens exposed in the ischemically injured heart allografts and 
needs further investigation. However, we believe that this is 
unlikely because the strong Th17 recall response of the sple-
nocytes from T-bet      /      recipients is in response to alloanti-
gen, and in general, the frequency of alloreactive T cells is 
signifi  cantly higher than that of autoreactive T cells. 
  In another model of vascular rejection, however, IL-17 
antagonism attenuated acute rather than chronic rejection 
(  52  ). It has been reported that an initial vascular infl  amma-
tion, characterized by perivascular and intraluminal lympho-
cytic infi   ltration, precedes development of the classical 
fi  broproliferative arteriosclerotic lesions of CAV (  11  ). This 
initial vascular infl  ammation likely represents a counterpart of 
acute rejection in clinical transplantation and is a harbinger of 
pathological changes of impending CAV or clinical chronic 
rejection. In our experiments with T-bet      /      recipients, this 
early vascular infl  ammation is so severe that acute rejection 
ensues, precluding assessment of the impact of T-bet defi  -
ciency on CAV. However, in WT recipients, vascular in-
fl   ammation of the grafts becomes apparent by 2 wk after 
transplantation and progresses to typical lesions of CAV by 
8 wk. Indeed, IL-17 neutralization in our model of CAV in 
T-bet      /      recipients resulted in a marked decrease in initial vas-
cular infl  ammation (  Fig. 6 C   and   Table II  ) and, consequently, 
prolongation of graft survival (  Fig. 6 A  ). Interestingly, IL-17 
neutralization converts the phenotype (in relation to CAV) 
of the T-bet      /      recipients to that of IFN-          /      recipients, 
and the grafts undergo delayed parenchymal rejection with 
minimal changes of CAV (  Fig. 6 C  ), similar to a previous re-
port in IFN-          /      recipients in this model (  11  ). This suggests 
that early vascular infl  ammation is mediated by CD4 Th17 
cells and contributes to the eventual development of CAV, 
and that even a brief antagonism of CD4 Th17 cells by IL-17 
neutralization aff  ords protection from CAV. 
  In summary, recent elucidation of a novel lineage of T-
helper Th17 cells (  18, 22, 25  ) has shed light on some of the 
    Table II.        Phenotype of graft-infi  ltrating leukocytes in T-bet     /     recipients with and without IL-17 neutralization 
Infi  ltrating cells T-bet      /      control Ig (day 14) T-bet      /      IL-17 neutralization (day 14) T-bet      /      IL-17 neutralization (day 40)
Lymphocytes 15.4   ±   2.1 3.2   ±   1.3 10.3   ±   3
Macrophages 21.6   ±   4.3 4.7   ±   1.8 13.6   ±   3
Neutrophils 18.4   ±   5.6 1.2   ±   0.3 4.6   ±   1.9
Eosinophils 96.1   ±   13.5 26.4   ±   6.5 71.7   ±   7.9
Total 151.1   ±   18.3 34.1   ±   6.9 100.3   ±   13.7
Five high-power fi  elds were counted per slide, with one slide each from three to four heart grafts per group. Results are presented as mean numbers of cells   ±   SD.3142 T-BET REGULATES CD4 TH17 CELLS AND ALLOGRAFT VASCULOPATHY   | Yuan et al. 
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